Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.
If you had told me in March, when the viral pandemic began, that we'd still be staying inside 5 months later, I wouldn't believe you. Yet COVID-19 has become one…
According to biotechnology Gilead Sciences, the FDA rejected a new drug application (NDA) for filgotinib. The drug, designed to treat patients with moderate to severe rheumatoid arthritis (RA), is known…
According to the World Health Organization (WHO), there were 228 million cases of malaria across the globe in 2018. Many of these were in African nations; in fact, the African…
Sometimes, researchers find beneficial medications during clinical trials. Other times, the therapy just falls short. According to Myasthenia Gravis News, the latter is true for Firdapse (amifampridine phosphate). The…
This past week, biopharmaceutical company Mustang Bio announced that their gene therapy candidate MB-107 received Rare Pediatric Disease Designation. The gene therapy candidate is designed to treat X-linked severe…
Did you know that over 25 million people worldwide take antidepressants? But even with this high usage, many researchers aren't sure exactly how antidepressants like selective serotonin reuptake inhibitors…
In many cases, autoimmune disorders like myasthenia gravis are treatable. However, there are some cases of refractory (treatment resistant) myasthenia gravis that presents an unmet patient need. However, researchers…
In an editorial piece published in the New England Journal of Medicine, Dr. Michael T. Melia, M.D., and Paul G. Auwaerter, M.D., note that up to 20% of patients with…
Recently, the Michael J. Fox Foundation (MJFF) awarded $1.4 million in funding for Modag, a drug developer whose solutions treat patients with neurodegenerative diseases. In fact, says Parkinson's News…
Do you want to make a difference in patient advocacy and rare disease education? Well, here's your chance. Every year, the Dystonia Medical Research Foundation (DMRF) holds a local…
This week, Regeneron Pharmaceuticals announced that their Biologics License Application (BLA) for evanicumab, a treatment for homozygous familial hypercholesterolemia (HoFH), was granted Priority Review status by the FDA. The…
Would you be shocked to find out that before Evrysdi, there were zero orally-administered drugs approved to treat patients with spinal muscular atrophy (SMA)? But now, things have changed. Last week,…
Nobody knows the exact cause of Parkinson's disease. However, many researchers believe that environmental triggers may play a factor. Now, the Michael J. Fox Foundation (MJFF) is encouraging American…
Recently, Daiichi Sankyo and AstraZeneca announced a clinical trial collaboration to determine whether using a combination of TAGRISSO (osimertinib) and patritumab deruxtecan (U3-1402) would be effective in treating patients…
Following positive data from two Phase 3 trials, the European Commission (EC) approved Cosentyx (secukinumab) for the treatment of pediatric psoriasis. Drug developer Novartis announced the news early last…
This year, the American Society of Retina Specialists (ASRS) held their annual meeting online. Many leaders in the field, such as Dr. Bobeck Modjtahedi, MD, attended to present new…
As society becomes increasingly technological, researchers are getting closer and closer to mapping the entire human genome. In facts, shares Medical XPress, we may be nearly there. While many…
Today, American Gene Technologies (AGT) announced that they will soon be beginning a Phase 1 clinical trial for AGT103-T, a potential treatment for HIV. The unique gene therapy, developed…
At the virtual Alzheimer's Association International Conference (AAIC), AC Immune reported positive preclinical trial data for ACI-12589, their forward-thinking diagnostic tool. ACI-12589 is a non-invasive alpha-synuclein positron emission tomography…
In a recent press release, Swedish biotechnology company Active Biotech announced that the first patient in their Phase 1b/2a clinical trial received a dose of tasquinimod. The trial will…
When Jessica Kalnas was growing up, her mother Judy thought her daughter was just clumsy. The youngest of six kids, Jessica was always falling over: off of her bike,…
According to Ryan McDonald of Cure Today, the FDA recently granted Breakthrough Therapy Designation to MK-6482, an investigational HIF-2α inhibitor developed by Merck. The orally-administered drug, designed to treat…
Within the last week, biotechnology company Levo Therapeutics announced results from the Phase 3 CARE-PWS clinical trial. During the trial, researchers examined the efficacy, safety, and tolerability of LV-101…
Rare disease or health-related foundations often encourage patient advocacy, research, and discussion around new treatments. According to Parkinson's News Today, the Parkinson's Foundation is doing their part in advancing…
Earlier this week, biotechnology company Time Technologies announced that its drug candidate SM-88 received Orphan Drug Designation from the FDA for the treatment of pancreatic cancer. The FDA defines…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
